NCT07619482Enrolling by invitationPhase 1/2
Topical Insulin for Glaucoma (TING2)
A Phase 1/2 Dose Escalation Followed by a Masked, Randomized, Placebo-Controlled Study to Evaluate Topical Insulin for Neuroprotection in Open Angle Glaucoma
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma. The study uses a phase 1/2 dose-escalation design followed by a masked, randomized, placebo-controlled phase. Insulin is formulated as preservative-free eye drops and delivered once daily. The primary objective is to determine the safety profile of topical insulin; secondary objectives assess effects on retinal structure, visual field, visual acuity, contrast sensitivity, and quality of life.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 26 May 2026
- Start date
- 10 Sept 2026
- Primary completion date
- 31 Oct 2028
- Lead sponsor
- Stanford University
- Diseases
- Glaucoma
- NCT number
- NCT07619482
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 90
- From 10 Sept 2026 to the primary completion date, 31 Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Limited Inclusion Criteria - All Groups:
- Provide written informed consent approved by the appropriate ethics committee
- Age 18 years or older
- Understand study procedures and have the ability and willingness to abide by all procedures during the study
- Capable of providing informed consent
- Diagnosis of glaucoma
- Only one eye per patient will be selected as the study eye; if both eyes meet inclusion criteria, the eye with worse visual acuity and/or visual field will be selected
- Limited Exclusion Criteria - All Groups:
- Pregnant or breastfeeding
- Presence of any ocular pathology other than glaucoma that contributes to severe vision loss (retinopathy, maculopathy, severe uveitis, keratopathy, etc.)
- Diagnosis of glucose intolerance, type 1 or type 2 diabetes mellitus
- Inability to perform reliable visual field testing
- Unable to provide informed consent
- Unable to complete the tests and follow-ups required by the study
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Byers Eye Institute at Stanford University Coordinator of this site? Confirm its status | Palo Alto | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.